Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent glp-1 a groundbreaking approach to diabetes management. These innovative medications function by mimicking the physiological actions of GLP-1, a hormone produced by the gut in response to consumption. By activating GLP-1 receptors in the pancreas, these agents enhance insulin secretio

The burgeoning landscape of novel treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting substantial weight loss – they exhibit intriguing variations in their pharmacol